Occupancy of dopamine D1, D2 and serotonin 2A receptors in schizophrenic patients treated with flupentixol in comparison with risperidone and haloperidol

Psychopharmacology

Volumn 190, Issue 2, 2007, Pages 241-249

  Reimold, M ^a,d   Solbach, C ^a   Noda, S ^b   Schaefer, J E ^b   Bartels, M ^b   Beneke, M ^c   Machulla, H J ^a   Bares, R ^a   Glaser, T ^c   Wormstall, H ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^c BAYER AG   (Germany)

^d PET Center   (Germany)

Author keywords

5 HT2A receptor; Dopamine D1 receptor; Dopamine D2 receptor; Flupentixol; Haloperidol; Positron emission tomography; Receptor occupancy; Risperidone

Indexed keywords

3 METHYLSPIPERONE C 11; 8 CHLORO 2,3,4,5 TETRAHYDRO 3 METHYL 5 PHENYL 1H 3 BENZAZEPIN 7 OL HYDROGEN MALEATE C 11; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; FLUPENTIXOL; FLUPENTIXOL DECANOATE; HALOPERIDOL; RACLOPRIDE C 11; RISPERIDONE; SEROTONIN 2A RECEPTOR; TRACER; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BINDING KINETICS; CATATONIC SCHIZOPHRENIA; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORPUS STRIATUM; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG RECEPTOR BINDING; FEMALE; FRONTAL LOBE; HUMAN; MALE; MIXED SCHIZOAFFECTIVE DISORDER; NEGATIVE SYNDROME; PARANOID SCHIZOPHRENIA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECEPTOR OCCUPANCY; RESIDUAL SCHIZOPHRENIA; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SIMPLE SCHIZOPHRENIA;

ADULT; ANTIPSYCHOTIC AGENTS; CORPUS STRIATUM; FEMALE; FLUPENTHIXOL; FRONTAL LOBE; HALOPERIDOL; HUMANS; MALE; MIDDLE AGED; POSITRON-EMISSION TOMOGRAPHY; RADIOLIGAND ASSAY; RECEPTOR, SEROTONIN, 5-HT2A; RECEPTORS, DOPAMINE D1; RECEPTORS, DOPAMINE D2; RISPERIDONE; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY;

EID: 33845758415     PISSN: 00333158     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00213-006-0611-0     Document Type: Article

References (44)

1. Abi-Dargham A, Gil R, Krystal J, Baldwin RM, Seibyl JP, Bowers M, van Dyck CH, Charney DS, Innis RB, Laruelle M (1998) Increased striatal dopamine transmission in schizophrenia: confirmation in a second cohort. Am J Psychiatry 155:761-767
2. Abi-Dargham A, Mawlawi O, Lombardo I, Gil R, Martinez D, Huang Y, Hwang DR, Keilp J, Kochan L, Van Heertum R, Gorman JM, Laruelle M (2002) Prefrontal dopamine D1 receptors and working memory in schizophrenia. J Neurosci 22(9):3708-3719
3. Andree B, Nyberg S, Ito H, Ginovart N, Brunner F, Jaquet F, Halldin C, Farde L (1998) Positron emission tomographic analysis of dose-dependent MDL 100,907 binding to 5-hydroxytryptamine2A receptors in the human brain. J Clin Psychopharmacol 18 (4):317-323
4. 11C]methyl)spiperone. Int J Rad Appl Instrum, A Appl Radiat Isot 37:433-434
5. 11C]-labelled raclopride. Specific dopamine-D2 receptor ligands. J Label Compd Radiopharm 24:931-940
6. Farde L, Nordstrom AL (1992) PET analysis indicates atypical central dopamine receptor occupancy in clozapine-treated patients. Br J Psychiatry Suppl (17):30-33
7. 2 dopamine receptor binding in the living human brain by PET. Science 231(4735):258-261
8. 2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine. Relation to extrapyramidal side effects. Arch Gen Psychiatry 49(7):538-544
9. Gattaz WF, Diehl A, Geuppert MS, Hubrich P, Schmitt A, Linde I, Maras A, Dittmann RW (2004) Olanzapine versus flupenthixol in the treatment of inpatients with schizophrenia: a randomized double-blind trial. Pharmacopsychiatry 37:279-285
10. Glaser T, Soyka M (1998) Flupentixol - typisches oder atypisches Wirkspektrum? Steinkopff, Darmstadt
11. Gründer G, Carlsson A, Wong DF (2003) Mechanism of new antipsychotic medications: occupancy is not just antagonism. Arch Gen Psychiatry 60(10):974-977
12. 11C-labelled SCH 23390 for the in vivo study of dopamine D-1 receptors using positron emission tomography. Int J Rad Appl Instrum, A Appl Radiat Isot 37:1039-1043
13. 2 receptors: homogenate binding and autoradiographic studies. Neurochem Int 30(3):277-290
14. Hyttel J, Larsen JJ, Christensen AV, Arnt J (1985) Receptor-binding profiles of neuroleptics. Psychopharmacology Suppl 2:9-18
15. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J Neurochem 76:1521-1531
16. 2 receptor explain the action of atypical antipsychotics?: a new hypothesis. Am J Psychiatry 158:360-369
17. 2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. Am J Psychiatry 156:286-293
18. 2 occupancy, clinical response, and side effects: a double-blind PET study of first-episode schizophrenia. Am J Psychiatry 157:514-520
19. 2 receptor occupancy. Arch Gen Psychiatry 57(6):553-559
20. Karlsson P, Farde L, Halldin C, Sedvall G (2002) PET study of D(1) dopamine receptor binding in neuroleptic-naive patients with schizophrenia. Am J Psychiatry 159(5):761-767
21. Kay SR, Fiszbein A, Opler LA (1987) The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 13(2):261-276
22. Kuehn KU, Meyer K, Maier W (2000) Flupentixol - ein partiell atypisches Neuroleptikum? Fortschr Neurol Psychiatr 68(Suppl 1):S38-S41
23. Lammertsma AA, Hume SP (1996) Simplified reference tissue model for PET receptor studies. Neuroimage 4:153-158
24. Laruelle M (2000) Imaging synaptic neurotransmission with in vivo binding competition techniques: a critical review. J Cereb Blood Flow Metab 20:423-451
25. 2 receptors in healthy subjects. J Nucl Med 35:743-754
26. Lieberman JA, Mailman RB, Duncan G, Sikich L, Chakos M, Nichols DE, Kraus JE (1998) Serotonergic basis of antipsychotic drug effects in schizophrenia. Biol Psychiatry 44(11):1099-1117
27. Logan J, Fowler JS, Volkow ND, Wang GJ, Ding YS, Alexoff DL (1996) Distribution volume ratios without blood sampling from graphical analysis of PET data. J Cereb Blood Flow Metab 16 (5):834-840
28. Lundberg T, Lindstrom L, Hartvig P, Reibring L, Agren H et al (1996) Serotonin-2 and dopamine-1 binding components of clozapine in frontal and striatum in the brain visualized by positron emission tomography. Psychiatry Res 67:1-10
29. Meltzer HY (1992) The importance of serotonin-dopamine interactions in the action of clozapine. Br J Psychiatry Suppl (17):22-29
30. 2 pKi values. J Pharmacol Exp Ther 251:238-246
31. 2-dopamine receptor occupancy in relation to antipsychotic drug effects: A double-blind PET trial of schizophrenic patients. Biol Psychiatry 33:227-235
32. 2 dopamine receptor occupancy in the living human brain. A PET study with risperidone. Psychopharmacology (Berl) 110:265-272
33. 2 dopamine receptor occupancy and plasma antipsychotic drug levels in man. Int Clin Psychopharmacol 10(Suppl 3):81-85
34. 2 receptor occupancy studies and clinical response. Br J Psychiatry Suppl (29):40-44
35. Nyberg S, Nilsson U, Okubo Y, Halldin C, Farde L (1998) Implications of brain imaging for the management of schizophrenia. Int Clin Psychopharmacol 13(Suppl 3):S15-S20
36. 2A receptor occupancy in schizophrenic patients. Am J Psychiatry 156:869-875
37. 2 receptors in schizophrenic patients studied by positron emission tomography. Life Sci 66 (25):2455-2464
38. Philipp M, Lesch OM, Walter H, Patras L, Kurtz G, Schmauß M, Seemann U, Roth G, Stöhr K, Dose M, Hetzel G, Ruhrmann S, Beneke M, Rappard F, Glaser T (2002) Wirksamkeit von Flupentixol vs Risperidon auf die Negativsymptomatik schizophrener Patienten. Psychopharmakotherapie 9:67-74
39. Philipp M, Lesch OM, Schmauss M, Dose M, Glaser T (2003) Comparative effectiveness of flupenthixol and risperidone on negative symptoms of schizophrenia. Psychiatr Prax 30(Suppl 2):S94-S96
40. Reimold M, Mueller-Schauenburg W, Becker GA, Reischl G, Dohmen BM, Bares R (2004) Non-invasive assessment of distribution volume ratios and binding potential: tissue heterogeneity and interindividually averaged time-activity curves. Eur J Nucl Med Mol Imaging 31(4):564-577
41. 123I-iodobenzamide single photon emission computed tomography in the drug-naive state and after neuroleptic treatment. Biol Psychiatry 43(9):660-665
42. Seeman P (2002) Atypical antipsychotics: mechanism of action. Can J Psychiatry 47:27-38
43. 2 receptors with clozapine: differentiation from other atypical antipsychotics. Am J Psychiatry 161(9):1620-1625
44. Weiner DM, Burstein ES, Nash N, Croston GE, Currier EA, Vanover KE, Harvey SC, Donohue E, Hansen HC, Andersson CM, Spalding TA, Gibson DF, Krebs-Thomson K, Powell SB, Geyer MA, Hacksell U, Brann MR (2001) 5-hydroxytryptamine2A receptor inverse agonists as antipsychotics. J Pharmacol Exp Ther 299(1):268-276